Nivolumab with chemotherapy improve outcomes in resectable non-small-cell lung cancer: NEJM
A new phase 3 clinical trial revealed that standard treatment with neoadjuvant nivolumab in combination with chemotherapy significantly improved the outcomes for patients with resectable non-small-cell lung cancer (NSCLC). The key findings of this study …